Prashant Kapoor, MD, and Shaji Kumar, MD, on Selinexor, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma

Posted: Tuesday, June 16, 2020

Prashant Kapoor, MD, and Shaji Kumar, MD, both of the Mayo Clinic, discuss initial results of the phase III BOSTON study—the first trial to evaluate the clinical benefit of selinexor, bortezomib, and dexamethasone for relapsed or refractory multiple myeloma.